# Farletuzumab ecteribulin

Source: https://onco.cc/drugs/farletuzumab-ecteribulin/  
OnCo record `farletuzumab-ecteribulin` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Farletuzumab ecteribulin is an antibody-drug conjugate from Eisai Inc., in registered phase 2 trials for metastatic cancer.

## Summary

Farletuzumab ecteribulin is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Eisai Inc., in metastatic cancer. An antibody-drug conjugate: an antibody against a tumour surface protein carries a cytotoxic payload into the cell. The registry record does not state the target or payload; the trial entries below carry the sponsor's description. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Also known as: MORAb-202
- Tags: pipeline; ctgov-ingest; registry-only
- Modality: Antibody-drug conjugate
- Mechanism: An antibody-drug conjugate: an antibody against a tumour surface protein carries a cytotoxic payload into the cell. The registry record does not state the target or payload; the trial entries below carry the sponsor's description.

## Sources

- ClinicalTrials.gov: trials of Farletuzumab ecteribulin: https://clinicaltrials.gov/search?intr=Farletuzumab%20ecteribulin

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Eisai](https://onco.cc/companies/eisai/)
- trials: [A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types](https://onco.cc/trials/nct04300556/)

---
JSON: https://onco.cc/api/v1/entities/farletuzumab-ecteribulin.json